Chronic Spontaneous Urticaria

Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria

Novartis remibrutinib has Phase 3 support in chronic spontaneous urticaria, with evidence of early symptom improvement and sustained efficacy through 52 weeks. This plan frames the result for BD teams, investors, and analysts, including regulatory context and what to watch next.

Dupixent Becomes First Biologic Approved for Chronic Spontaneous Urticaria in Children Ages 2-11

Sanofi and Regeneron's Dupixent receives FDA approval as first biologic treatment for children with uncontrolled chronic spontaneous urticaria.

Dupixent Becomes First Biologic Approved for Chronic Spontaneous Urticaria in Children Ages 2-11

Sanofi's Dupixent receives FDA approval as first biologic treatment for chronic spontaneous urticaria in young children, expanding pediatric treatment options.

Dupixent Becomes First Biologic Approved for Children Ages 2-11 with Chronic Spontaneous Urticaria

Sanofi's Dupixent receives FDA approval as first biologic treatment for young children with uncontrolled chronic spontaneous urticaria, expanding pediatric options.